Lobbying

Fulcrum Therapeutics FULC's latest lobbying report covers Q2 2026, at $60K. The four quarters Q3 2025–Q2 2026 total $190K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Pharmacy.

Fulcrum TherapeuticsFULC

Fulcrum Therapeutics stock page

Latest quarter
$60K
Q2 2026 · 1 reports
Last 12 months
$190K
Last 4 quarters
vs last quarter
+20.0%
Q2 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Fulcrum Therapeutics lobbying by quarter
Fulcrum Therapeutics lobbying by quarter
QuarterAmountReports
Q4 2022$30K1
Q1 2023$30K1
Q2 2023$30K1
Q3 2023$30K1
Q4 2023$30K1
Q1 2024$30K1
Q2 2024$60K1
Q3 2024$60K1
Q4 2024$01
Q1 2025$40K1
Q2 2025$40K1
Q3 2025$40K1
Q4 2025$40K1
Q1 2026$50K1
Q2 2026$60K1

Policy issues the reports name

  • Health issues10 reports
  • Pharmacy2 reports

A report that names several issues counts once for each.

Who was lobbied

  • HOUSE OF REPRESENTATIVES12 reports
  • SENATE12 reports
  • Health & Human Services, Dept of (HHS)1 reports
  • White House Office1 reports

Firms it paid

Firm
The KPM Group DC$300K9 quarters
The McManus Group$270K6 quarters

Former officials lobbying for it

No lobbyist with a covered position.

Lobbying reports

Filed by
07/20for Q2The McManus Group$60K
04/20for Q1The McManus Group$50K
01/20for Q4 2025The McManus Group$40K
25/10/20for Q3 2025The McManus Group$40K
25/07/21for Q2 2025The McManus Group$40K
25/05/06for Q1 2025The McManus Group$40K
25/01/21for Q4 2024The KPM Group DCUnder $5,000
25/01/17for Q1 2025The McManus GroupUnder $5,000
24/10/21for Q3 2024The KPM Group DC$60K
24/07/19for Q2 2024The KPM Group DC$60K
24/04/19for Q1 2024The KPM Group DC$30K
24/01/22for Q4 2023The KPM Group DC$30K
23/10/20for Q3 2023The KPM Group DC$30K
23/07/19for Q2 2023The KPM Group DC$30K
23/04/20for Q1 2023The KPM Group DC$30K
23/01/19for Q4 2022The KPM Group DC$30K